Featured Research

from universities, journals, and other organizations

Allicin In Wonderland: Scientists 'Weaponize' An Antibody To Deliver Continuous Attacks On Cancer Cells

Date:
May 3, 2005
Source:
Weizmann Institute
Summary:
In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin."

In a recent study published in Molecular Cancer Therapeutics, researchers at the Weizmann Institute of Science paired the active ingredient of a garden remedy with advanced bio-technology to deliver a powerful punch against cancer. The cancer killing effectiveness lies in their technique of arming a cancer-targeting antibody with the destructive potential of the dietary molecule otherwise known as "allicin."

Allicin is the product of an interaction between an enzyme, alliinase, and the small chemical alliin, which occurs naturally in plants such as garlic and onion as a defense mechanism against soil fungi, bacteria and parasites. Allicin molecules can easily penetrate biological membranes and kill cells, but their potency is short-lived hence the difficulty in finding a system to deliver them to a specific site. "The medicinal value of garlic is no longer an ancient Chinese secret," says the Institute’s Prof. David Mirelman. "Years of scientific research led to the identification and understanding of allicin’s mode of activity and we are currently studying ways to target and deliver its toxic punch."

The team, including Mirelman, Prof. Meir Wilchek, Drs. Fabian Arditti, Talia Miron and Aharon Rabinkov of the Biological Chemistry Department, and Prof. Yair Reisner of the Immunology Department, together with Prof. Berrebi of Rehovot’s Kaplan Hospital, adopted an approach that fastens the enzyme alliinase onto a specific antibody already in clinical use, Rituximab, designed to target and lock on to the surface of certain types of cancer cells such as lymphoma. When administered alone, Rituximab serves as a marker and docking point for the body's own immune system to kill the cancer cell. The Institute team demonstrated that cancer cells could be destroyed more efficiently by arming this antibody: They first chemically bound alliinase to Rituximab and then injected this conjugate into mice that had been implanted with human lymphoma cancer cells. As predicted, the Rituximab, with the attached alliinase in tow, soon found and bound to the target cancer cells. Subsequently, the mice were repeatedly injected with the inert chemical alliin which, upon contact with alliinase, was processed into allicin molecules directly on the cancer cell's surface. Within three days, almost all of the human lymphoma cancer cells were destroyed in those mice treated with the conjugate and alliin, while hardly any cancer cell destruction occurred in the control mice who received the conjugate alone.


Although other approaches use a method that directly binds anti-cancer drug molecules to an antibody, this study applied a method Mirelman refers to as "weaponizing" an antibody, so called because it affords the continuous production and delivery of cancer-killing bullets: The alliinase that is bonded to the Rituximab sits on the target cell and continuously reacts with alliin molecules that are injected at intervals, producing a steady supply of allicin to penetrate and kill the cancer. The production of allicin can be "turned off" by the ceasing the administration of the ammunition - alliin.

"This study was a proof of principle," says Mirelman, "demonstrating the effectiveness of this technology for the selective killing of unwanted cells." Given that the active component is a familiar dietary element, and that specific antibodies such as Rituximab are increasingly in clinical use, the scientists hope the way will be paved for the new technology to be developed into useful therapies.

Prof. David Mirelman’s research is supported by the Y. Leon Benoziyo Institute for Molecular Medicine; the M.D. Moross Institute for Cancer Research; Ms. Erica A. Drake, Scarsdale, NY; Mr. and Mrs. Henry Meyer, Wakefield, RI; Mr. Nathan Minzly, UK; and the late Claire Reich, Forest Hills, NY. Prof. Mirelman is the incumbent of the Besen-Brender Chair of Microbiology and Parasitology.

Story Source:

The above story is based on materials provided by Weizmann Institute. Note: Materials may be edited for content and length.


Cite This Page:

Weizmann Institute. "Allicin In Wonderland: Scientists 'Weaponize' An Antibody To Deliver Continuous Attacks On Cancer Cells." ScienceDaily. ScienceDaily, 3 May 2005. <www.sciencedaily.com/releases/2005/05/050503104540.htm>.
Weizmann Institute. (2005, May 3). Allicin In Wonderland: Scientists 'Weaponize' An Antibody To Deliver Continuous Attacks On Cancer Cells. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2005/05/050503104540.htm
Weizmann Institute. "Allicin In Wonderland: Scientists 'Weaponize' An Antibody To Deliver Continuous Attacks On Cancer Cells." ScienceDaily. www.sciencedaily.com/releases/2005/05/050503104540.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins